Genmab A/S (Nasdaq: GMAB) has announced a strategic partnership with Anthropic to integrate advanced artificial intelligence into its research and development (R&D) operations, aiming to accelerate clinical development and enhance scientific efficiency. Under the agreement, Genmab and Anthropic will co-develop custom, Claude-powered agentic AI solutions tailored to support Genmab’s clinical programs. These AI tools will assist teams in processing complex data, analyzing scientific information, and generating documentation—always within strict guardrails and under human oversight—to streamline workflows, improve consistency, and increase agility across critical regulatory milestones. Tahamtan Ahmadi, M.D., Ph.D., Executive Vice President and Chief Medical Officer at Genmab, emphasized that the collaboration marks a pivotal step in transforming Genmab’s R&D into a more scalable, digitally enabled engine aligned with its long-term AI strategy. By reducing manual workloads and enabling greater operational scale, the partnership will allow scientists and medical professionals to focus more time on high-value strategic and innovative tasks, ultimately accelerating the path from discovery to patient impact. Genmab, a global biotechnology leader headquartered in Copenhagen, Denmark, has been advancing a robust pipeline of antibody-based therapies for cancer and other serious diseases for over two decades. Its portfolio includes eight approved medicines and multiple late-stage investigational programs targeting solid tumors and hematological malignancies. The company continues to invest heavily in digital innovation and AI-driven capabilities to support the expansion and execution of its growing pipeline. Kate Jensen, Head of Americas at Anthropic, highlighted the significance of applying AI to clinical development—a process that is highly regulated and directly impacts patient outcomes. She noted that Genmab’s commitment to innovation and patient-centricity makes it an ideal partner for deploying AI responsibly. The collaboration focuses on building custom agentic AI systems designed not to replace human expertise but to empower teams to tackle the most complex scientific challenges, thereby speeding up the delivery of life-changing therapies. This partnership comes amid broader industry shifts as pharmaceutical and biotech companies increasingly adopt AI to optimize drug discovery and development. Genmab’s move reflects a growing trend toward integrating AI tools into core R&D processes while maintaining rigorous oversight and ethical standards. The announcement underscores the expanding role of AI in life sciences, particularly in handling vast datasets and accelerating timelines in clinical research. While AI’s use in training models has recently faced legal scrutiny—most notably in a landmark ruling where Judge William Alsup found training on legally purchased books to be fair use—the Genmab-Anthropic collaboration focuses on downstream applications within controlled, regulated environments. The partnership does not involve the use of unlicensed or pirated data, and all AI deployment is designed to operate within defined compliance and safety parameters. This approach aligns with Genmab’s commitment to responsible innovation and regulatory integrity. As AI reshapes the future of medicine, collaborations like this one demonstrate how cutting-edge technology can be leveraged to enhance scientific rigor, improve efficiency, and ultimately bring transformative treatments to patients faster. With this strategic alliance, Genmab is positioning itself at the forefront of a new era in biopharmaceutical R&D, where human expertise and AI work in concert to drive progress.